| Target Price | ¥1,708.50 |
| Price | ¥1,763.00 |
| Deviation |
3.09%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Kuraray 2027 .
The average Kuraray target price is ¥1,708.50.
This is
3.09%
register free of charge
¥2,940.00
66.76%
register free of charge
¥1,393.80
20.94%
register free of charge
|
|
| A rating was issued by 16 analysts: 1 Analysts recommend Kuraray to buy, 9 to hold and 6 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Kuraray stock has an average upside potential 2027 of
3.09%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion ¥ | 808.45 | 871.06 |
| 2.23% | 7.75% | |
| EBITDA Margin | 17.76% | 16.90% |
| 13.78% | 4.84% | |
| Net Margin | 0.92% | 3.99% |
| 75.92% | 331.94% |
11 Analysts have issued a sales forecast Kuraray 2026 . The average Kuraray sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an Kuraray EBITDA forecast 2026. The average Kuraray EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Kuraray Analysts have issued a net profit forecast 2026. The average Kuraray net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share ¥ | 23.60 | 115.47 |
| 75.49% | 389.28% | |
| P/E | 15.27 | |
| EV/Sales | 0.85 |
11 Analysts have issued a Kuraray forecast for earnings per share. The average Kuraray EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


